Roche Holding reported CHF6.87B in Net Income for its fiscal semester ending in June of 2026.





Net Income Change Date
AbbVie USD 4.22B 605M Sep/2026
Alcon AG USD 260M 71M Sep/2026
Almirall EUR 24.25M 4.68M Jun/2026
Amgen USD 3.86B 1.49B Sep/2026
AstraZeneca USD 3.12B 610M Sep/2026
Bayer EUR -672M 891M Sep/2026
Biogen USD 97.5M 222M Jun/2026
Bristol-Myers Squibb USD 2.16B 1.16B Sep/2026
Eli Lilly USD 7.1B 301M Jun/2026
Fresenius EUR 371M 11M Sep/2026
Fresenius Medical Care EUR 160M 58.38M Sep/2026
Genmab DKK 303M 250M Jun/2026
Gilead Sciences USD -10.5B 12.52B Jun/2026
GlaxoSmithKline GBP 1.54B 1.11B Sep/2026
GRIFOLS EUR 162M 8M Sep/2026
Hikma Pharmaceutical USD 164M 45M Dec/2025
Lakefront Biotherapeutics EUR -2.67M 4.78M Sep/2026
Lonza CHF 426M 119M Jun/2025
Merck EUR 450M 40M Sep/2026
Merck USD 5.07B 6.4B Sep/2026
Novartis USD 1.2B 2.06B Sep/2026
Orion EUR 167.6M 27.4M Sep/2026
Pfizer USD 3.24B 3.49B Sep/2026
Philips EUR 27M 357M Sep/2026
Recordati EUR 137.43M 20.82M Sep/2026
Regeneron Pharmaceuticals USD 1.3B 569.7M Jun/2026
Roche Holding CHF 6.87B 1.4B Jun/2026
Sanofi EUR 3.02B 2.68B Sep/2026
UCB EUR 1.08B 608M Dec/2025